Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
"Transloading of Tumor Antigen-Derived Peptides into Antigen-Presenting Cells."
May 26th, 1997
According to the authors' abstract of an article published in Proceedings of the National Academy of Sciences of the United States of America, "The discovery of a steadily growing number of tumor antigens (TAs) has made generic, cell-free, peptide-based cancer vaccines a possible alternative to cytokine-transfected autologous cellular cancer vaccines. The major drawback of peptide vaccines, however, is the poor immunogenicity of peptides. It is commonly thought that for the induction of an effective anticancer immune response, antigen-presenting cells (APCs) have to display TA-derived peptides to T lymphocytes. Polycationic amino acids have been employed in the past to enhance transport...
Source: Cancer Weekly (1997-05-26)
|
|
Advertisement |
|
|
